HQL
Financial ServicesTekla Life Sciences Investors · Asset Management · $520M
What is Tekla Life Sciences Investors?
Tekla Life Sciences Investors (HQL) is a closed-end equity fund managed by Tekla Capital Management LLC, focused on the global life sciences sector. Formed in 1992 and domiciled in the United States, it targets growth-oriented small-cap companies across healthcare and adjacent industries.
HQL invests in publicly traded companies across biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical devices, healthcare IT, hospitals, and even agriculture and environmental management. The fund uses fundamental analysis — evaluating management experience, market positioning, technological expertise, and capital access — to build a portfolio benchmarked against the NASDAQ Biotech Index and the S&P 500.
The fund was formed on February 20, 1992, and is headquartered in Philadelphia, US.
- Closed-end fund structure with exchange-traded shares
- Concentrated exposure to life sciences and biotech equities
- Global small-cap growth stock focus
- Regular dividend distributions to shareholders
Is HQL a Good Stock to Buy?
UQS Score rates HQL as Below Average overall.
The fund's strongest attributes appear in its Quality pillar, which registers as Good, reflecting reasonable portfolio construction discipline. Valuation is rated Attractive, suggesting the fund's shares may trade at a discount relative to assessed fair value — a characteristic common among closed-end funds.
Both the Moat and Growth pillars are rated Weak, indicating limited competitive differentiation and subdued growth prospects relative to peers.
Sign up for a Pro account to see the exact pillar breakdown and the full financial metrics behind HQL's UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does HQL pay dividends?
Yes — Tekla Life Sciences Investors pays a dividend.
HQL pays a regular dividend, which is a defining feature of many closed-end funds seeking to return income to shareholders. The distributions may include income, capital gains, or return of capital depending on portfolio activity. Investors focused on income often consider closed-end fund dividends alongside the fund's discount or premium to net asset value.
When does HQL report earnings?
Tekla Life Sciences Investors reports on a quarterly cadence, consistent with US-listed closed-end funds.
As a closed-end fund, HQL's reported results reflect portfolio valuations, realized gains, and distribution activity rather than traditional operating revenues. Performance is closely tied to movements in biotech and life sciences equities, which can be volatile.
For the most recent quarter's results and net asset value updates, see Tekla Capital Management's investor relations page.
HQL Price History
+50.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Tekla Life Sciences Investors?
Based on Tekla Life Sciences Investors's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
HQL Long-term Outlook
HQL's Growth pillar is rated Weak, reflecting the challenging environment for small-cap biotech and life sciences equities, where many holdings may be pre-revenue or dependent on clinical outcomes. The Neutral Risk rating suggests the fund's overall risk profile is neither unusually elevated nor particularly defensive. The Attractive Valuation label may offer a potential entry point for investors comfortable with sector volatility.
Growth drivers
- Potential re-rating of biotech small-caps if interest rates ease and risk appetite returns
- Innovation cycles in pharmaceuticals, diagnostics, and medical devices within the portfolio
- Closed-end fund discount narrowing as investor sentiment toward life sciences improves
Key risks
- Weak Moat rating reflects limited structural protection against portfolio underperformance
- Small-cap biotech concentration amplifies sector-specific volatility and binary event risk
- Weak Growth pillar signals near-term headwinds for the underlying holdings
HQL vs Peers
HQL operates in the closed-end and specialty fund space alongside several other income- and equity-focused vehicles.
Aimia is a Canadian holding company with a diversified investment portfolio, contrasting with HQL's singular focus on life sciences equities.
Eagle Point Credit focuses on collateralized loan obligation equity tranches, offering credit-market exposure rather than HQL's equity-driven biotech strategy.
Canadian Banc Corp targets Canadian financial sector equities, making its sector concentration and geographic focus quite different from HQL's global life sciences mandate.
Frequently Asked Questions
What does Tekla Life Sciences Investors do?
Tekla Life Sciences Investors is a closed-end equity fund that invests in publicly traded companies across the life sciences sector globally. Its focus spans biotechnology, pharmaceuticals, diagnostics, medical devices, healthcare IT, and adjacent industries like agriculture and environmental management, with an emphasis on small-cap growth stocks.
Does HQL pay dividends?
Yes, HQL pays a regular dividend. As a closed-end fund, its distributions can include income, realized capital gains, or return of capital depending on portfolio activity. Investors should review the fund's distribution notices to understand the composition of each payment.
When does HQL report earnings?
Tekla Life Sciences Investors reports on a quarterly cadence, consistent with US-listed closed-end funds. For the most current net asset value data and quarterly results, visit Tekla Capital Management's investor relations page directly.
Is HQL a good stock to buy?
UQS Score rates HQL as Below Average overall. The Valuation pillar is Attractive and Quality is Good, but Moat and Growth are both Weak. Whether HQL fits a portfolio depends on an investor's income goals, sector views, and risk tolerance. See the full pillar breakdown on uqs-score.com.
Is HQL overvalued?
The UQS Valuation pillar for HQL is rated Attractive, suggesting the fund's shares do not appear overvalued relative to assessed fair value. Closed-end funds can trade at discounts to net asset value, which may contribute to this assessment. Full valuation metrics are available to Pro members.
How does HQL compare to its competitors?
HQL is distinct from peers like Eagle Point Credit and Canadian Banc Corp in its singular focus on global life sciences equities. While those funds target credit markets or financial sector stocks, HQL concentrates on biotech and healthcare innovation — a higher-volatility, growth-oriented mandate.
What is HQL's market cap bracket?
HQL is classified as a small-cap fund. Closed-end funds are sized by their total net assets and market capitalization of traded shares, and HQL falls within the small-cap range, which may affect liquidity and trading volume relative to larger fund vehicles.
Who founded Tekla Life Sciences Investors?
The fund was formed on February 20, 1992, and was formerly known as H&Q Life Sciences Investors. It is managed by Tekla Capital Management LLC. For detailed founding history and management background, Tekla Capital Management's official website is the authoritative source.
Is HQL a long-term quality investment?
As a long-term quality indicator, HQL's UQS Score of Below Average reflects meaningful weaknesses in Moat and Growth alongside a Good Quality rating. Long-term suitability depends on whether an investor believes in the life sciences sector's trajectory and can tolerate small-cap biotech volatility. Pro members can view the complete analysis.
What is the main competitive advantage of Tekla Life Sciences Investors?
HQL's primary differentiation is its specialized focus on life sciences — a sector requiring deep domain expertise in areas like drug development, regulatory pathways, and medical technology. Managed by Tekla Capital Management, the fund applies fundamental analysis to identify growth opportunities across the healthcare innovation landscape.
Unlock Full HQL Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores across Quality, Moat, Growth, Risk, and Valuation
- ✓Access full financial metrics and fund-level data
- ✓Compare HQL against closed-end fund and sector peers
- ✓See the complete analyst view available to Pro members
- ✓Track changes to HQL's UQS Score over time
Pro Analysis
HQL — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | 50.2 | 73.5 | 16.0 | 24.9 | 54.4 | 97.7 | +0.3 |
| Apr 25, 2026 | 49.9 | 73.5 | 16.0 | 24.9 | 54.4 | 96.1 | -0.3 |
| Apr 21, 2026 | 50.2 | 73.5 | 16.0 | 24.9 | 54.4 | 97.7 | +0.1 |
| Apr 20, 2026 | 50.1 | 73.5 | 16.0 | 24.9 | 54.4 | 97.5 | -0.2 |
| Apr 18, 2026 | 50.3 | 73.5 | 16.0 | 24.9 | 54.4 | 98.3 | -0.2 |
| Apr 2, 2026 | 50.5 | 73.5 | 16.0 | 24.9 | 54.4 | 100.0 | — |
HQL — Pillar Breakdown
Quality
— 73.5/100 (25%)Tekla Life Sciences Investors shows solid profitability with healthy returns on capital and reasonable margins.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 24.9/100 (20%)Tekla Life Sciences Investors faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 54.4/100 (15%)Tekla Life Sciences Investors has some risk factors including moderate leverage or solvency concerns.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 98.5/100 (15%)Tekla Life Sciences Investors appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
Enterprise value multiple relative to sector median.
Moat
— 16/100 (25%)Tekla Life Sciences Investors operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for HQL.
Score Composition
Financial Data
More Stock Analysis
How is the HQL UQS Score Calculated?
The UQS (Unified Quality Score) for Tekla Life Sciences Investors is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Tekla Life Sciences Investors's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Tekla Life Sciences Investors is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.